Uni Pharma is a leading pharmaceutical company founded in 1998 with a mission to provide the best medical options for patients. Committed to professionalism, enthusiasm, integrity, care, and responsibility, Uni Pharma offers a wide range of medical diagnostics, pharmaceuticals, and medical devices. Their medical diagnostics cover cancer and disease diagnosis in six major treatment areas, including colorectal surgery, gynecology, orthopedics, neurology, anesthesia, and cardiology.

Uni Pharma serves major medical centers, regional hospitals, local hospitals, and clinics as their primary customers. In addition to their existing product portfolio, Uni Pharma has expanded into the development of biopharmaceuticals and self-paying products. They have obtained domestic production permits for tumor marker Onko-Sure DR-70 and initiated export operations.

Uni Pharma's goal is to enter the markets of major Asia-Pacific countries within three years and eventually expand to regional and global markets. With a comprehensive organizational structure and a team of talented professionals, Uni Pharma possesses the rare capability of vertical integration in research and development, clinical trials, and business marketing. They are transitioning from traditional pharmaceutical distributors to a comprehensive research and development company, focusing on self-branded products and disease diagnostics.

Uni Pharma's future plans include continuous investment in medical research and the establishment of a central laboratory to meet the growing demand for cancer testing and personalized medical products. They remain committed to their core values, striving to develop innovative products and expand their business scope for the benefit of society and humanity